BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Mobilicom: ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Mobilicom Ltd. (Nasdaq:MOB) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
RedChip Companies將在本週六美國東部時間晚上7點在Bloomberg電視臺贊助的節目RedChip Show上播出針對BioVie， Inc. (納斯達克：BIVI)和Mobilicom Ltd. (Nasdaq：MOB)的訪談。Bloomberg TV估計在美國約7300萬個家庭可以接收。小公司股票、大鈔票Bloomberg電視臺贊助的節目RedChip Show將於本週六6月22日美國東部時間晚上7點播放，預計可以在美國約7300萬個家庭接收。
Access the interviews in their entirety at:
Soligenix:
BioVie:
BioVie：
Mobilicom:
Mobilicom:
In an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs targeting unmet medical needs in neurodegeneration and liver disease. BioVie's lead asset, bezisterim (formerly NE3107), has demonstrated the ability to modulate TNFα production, leading to significant clinical improvements. Patients treated with bezisterim experienced reduced inflammation and insulin resistance, improved motor control and "morning on" symptoms in Parkinson's disease (PD), enhanced cognition and function, and better brain imaging scans in Alzheimer's disease (AD), as well as reduced DNA methylation levels. The Company's strategic priorities include launching a Phase 2b trial for Parkinson's in Fall 2024, initiating a Phase 3 trial for Alzheimer's in mid-2025 with a new once-daily formulation of bezisterim, continuing partnering discussions for bezisterim's geographic rights, and commencing an ascites Phase 3 trial upon identifying a suitable partner.
在一次獨家採訪中，BioVie的總裁兼首席執行官Cuong Do將分享有關公司針對神經退行性和肝病等未滿足醫學需求的晚期臨床項目管道的見解。BioVie的主要資產bezisterim（前NE3107）已經證明其調節TNFα的產生能力，從而帶來了重大的臨床改善。接受bezisterim治療的患者經歷了氣體降低和胰島素抵抗，改善了帕金森氏症（PD）運動控制和“晨起症狀”，提高了認知和功能，並在阿爾茨海默病（AD）方面改善了腦成像掃描，以及降低了DNA的甲基化水平。該公司的戰略重點包括在2024年秋季啓動針對帕金森病的二期試驗，在2025年中期啓動使用新的一天一次的製劑的阿爾茨海默病三期試驗bezisterim，持續尋找bezisterim地理權益的合作伙伴，並在確定合適的合作伙伴後啓動一項腹水三期試驗。
Oren Elkayam, Founder and CEO of Mobilicom, appears on the RedChip Small Stocks, Big Money show on Bloomberg TV to provide a corporate update. Mobilicom presents a strong investment opportunity with its comprehensive and proprietary technology suite. The company's products, including SkyHopper Datalinks, Ground Control Systems, Mobile Mesh Networking, the ICE Cybersecurity Suite, and CONTROLiT cloud management, form the core 'brain' of drones, providing control, guidance, and cybersecurity. Mobilicom's intellectual property, comprising trade secrets and 34 patent claims across two patent families, underscores its innovation leadership. With a global footprint, the company has secured over 50 customers in 18 countries and achieved 50 "design wins," indicating significant market penetration and long-term revenue potential. Mobilicom generated 43% revenue growth with 59% gross margin in 2023, and ended the year with a strong cash balance of $8.4 million. Combined with a narrowing monthly burn rate, this affords Mobilicom a long cash runway to implement its strategic plans, capture market share, and ramp revenues.
Mobilicom的創始人兼首席執行官Oren Elkayam出現在Bloomberg電視臺RedChip Show上，提供公司更新。Mobilicom提供了應對不斷增長的國防和商業無人機和機器人市場的安全強大解決方案。公司的產品，包括SkyHopper Datalinks，Ground Control Systems，Mobile Mesh Networking，ICE Cybersecurity Suite以及CONTROLiT雲管理，構成了無人機的核心“大腦”，提供控制，導引和網絡安全。Mobilicom的專有技術組合，包括商業祕密和兩個專利家族的34項專利權主張，強調了其創新領導地位。公司在全球範圍內擁有50多個客戶，遍佈18個國家，並實現了50個“設計勝利”，顯示了其在市場滲透和長期營收潛力方面的重要性。Mobilicom在2023年實現了43%的營業收入增長和59%的毛利率，並以840萬美元的強勁現金餘額結束了該年。加上月度燒錢速率的下降，這爲Mobilicom提供了長期的現金航道，以實施其戰略計劃，佔領市場份額和提高營收。小公司股票、大鈔票在Bloomberg電視臺的RedChip Show上，Mobilicom的創始人兼首席執行官Oren Elkayam更新了公司動態。Mobilicom是國防和商業無人機和機器人市場的領先提供商，擁有廣泛的經過實地驗證的技術組合，包括網絡安全，軟件，硬件和專業服務，可爲無人機和機器人提供動力，連接，導引和安全。在50多個客戶中，包括全球最大的無人機制造商，Mobilicom的端到端解決方案用於使任務實現。34個專利聲明跨越兩個專利家族的Mobilicom的知識產權，強調了其創新領導地位。通過全球部署，公司已在18個國家獲得了50多個客戶，並實現了50個“設計勝利”，顯示了其在市場滲透和長期收益潛力方面的重要性。Mobilicom在2023年實現了43%的營業收入增長和59%的毛利率，並以840萬美元的強勁現金餘額結束了該年。加上月度燒錢速率的下降，這爲Mobilicom提供了長期的現金航道，以實施其戰略計劃，佔領市場份額和提高營收。
About BioVie Inc.
BioVie股份有限公司（NASDAQ：BIVI）是一家臨床階段公司，致力於開發治療神經系統和神經退行性疾病以及先進肝病的創新藥物療法。
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of ERK and NFκB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration ("FDA") Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit .
BioVie Inc. (NASDAQ: BIVI)是一家國內處於臨床階段的公司，致力於研發針對神經和神經退行性疾病以及先進肝病的創新藥物療法。在神經退行性疾病中，公司的藥物候選bezisterim抑制ERK和NFκB（例如，TNF信號轉導）的炎症活化，導致神經炎症和胰島素抵抗，但不影響它們的穩態功能（例如，胰島素信號轉導和神經元生長和存活）。都是阿爾茨海默病（AD）和帕金森氏症（PD）的驅動因素。在肝病方面，公司的孤兒藥物候選BIV201（連續輸注替利福汀），經美國食品和藥品管理局（“FDA”）加速審批，正在評估中，並已收到FDA關於對由慢性肝硬化引起的腹水進行BIV201三期臨床測試設計的指導。這種活性物質在美國和大約40個國家中被批准用於治療晚期肝硬化的相關併發症。有關更多信息，請訪問。
About Mobilicom
關於Mobilicom
Mobilicom is a leading provider of cybersecure robust solutions for the rapidly growing defense and commercial drones and robotics market. Mobilicom's large portfolio of field-proven technologies includes cybersecurity, software, hardware, and professional services that power, connect, guide, and secure drones and robotics. Through deployments across the globe with over 50 customers, including the world's largest drone manufacturers, Mobilicom's end-to-end solutions are used in mission-critical functions.
Mobilicom是國防和商業無人機和機器人市場的領先提供商，提供穩健的網絡安全解決方案。Mobilicom的大型技術組合包括網絡安全，軟件，硬件和專業服務，可爲無人機和機器人提供動力，連接，導引和安全。全球範圍內，Mobilicom已經爲市場領先的無人機制造商等50多個客戶提供端到端解決方案，並實現了50個“設計勝利”，顯示了其在市場滲透和長期重要性的市場追求及長期收益潛力。
For investors, please use
For company, please use
對於投資者，請使用
對於公司，請使用
About RedChip Companies
關於RedChip公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip公司是一家國際投資者關係、媒體和研究公司，是一家美國《Inc.》雜誌5000強公司，專注於微型市值和小市值公司。32年來，RedChip爲客戶提供了具體、可衡量的成果。我們的新聞簡報，“小公司股票、大鈔票”，每週在線上向6萬投資者發送。RedChip已經開發出行業中最全面的服務平台，爲微型市值和小市值公司提供以下服務：股票研究的全球分銷網絡；在美國主要城市進行散戶和機構路演；外發營銷給股票經紀人、RIA、機構和家族辦公室；數字媒體投資者關係平台，爲股東帶來數百萬次獨特的投資者瀏覽量；投資者網絡研討會和集體電話；電視節目，“小公司股票、大鈔票”，每週在Bloomberg US播出；在地方和全國市場上的電視廣告；公司和產品視頻；網站設計；傳統投資者關係服務，包括新聞稿撰寫、投資者演示文稿的製作、季度電話會議劇本的編寫、戰略諮詢、融資等。小公司股票、大鈔票在線向6萬投資者每週發送的電子郵件新聞簡報，“小公司股票、大鈔票”小公司股票、大鈔票在Bloomberg US每週播出的電視節目“小公司股票、大鈔票”
To learn more about RedChip's products and services, please visit:
要了解更多有關RedChip的產品和服務的信息，請訪問：
"Discovering Tomorrow's Blue Chips Today"
“發現明日的藍籌股”
Follow RedChip on LinkedIn:
在LinkedIn上關注RedChip：
Follow RedChip on Facebook:
在Facebook上關注RedChip：
Follow RedChip on Instagram:
在Instagram上關注RedChip：
Follow RedChip on Twitter:
在Twitter上關注RedChip：
Follow RedChip on YouTube:
在YouTube上關注RedChip：
Follow RedChip on Rumble:
在Rumble上關注RedChip：
Subscribe to our Mailing List:
訂閱我們的郵件列表：
Contact:
聯繫方式：
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
SOURCE: RedChip
來源：RedChip
譯文內容由第三人軟體翻譯。
